CAMBRIDGE, Mass., Feb. 4 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) launches an updated and revised website (http://www.biopure.com) on February 4, 2008. The redesign includes a website for the Oxyglobin veterinary product (http://www.oxyglobin.com) and the company's South Africa site (http://www.hemopure.co.za) where Hemopure(R) [hemoglobin glutamer - 250 (bovine)] is marketed for the treatment of acute anemia in adult surgery patients. New website features include a video case study of Oxyglobin in use, Notes from Zaf, where CEO Zafirelis will comment on Biopure concerns and events, and Dear Zaf where visitors to the site can ask questions of the CEO. Zaf's responses will be posted from time to time on the site.
The revised http://www.biopure.com site reflects the growing importance of the web as a direct communication tool and the increasing demand for 24/7 information by a variety of people, including the public, the investment community, and the news media.
Biopure Corporation develops, manufactures and markets pharmaceuticals,
called oxygen therapeutics, that are intravenously administered to deliver
oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250
(bovine)], or HBOC-201, is approved for sale in South Africa for the
treatment of surgical patients who are acutely anemic. Biopure has applied
in the United Kingdom for regulatory approval of a proposed orthopedic
surgical anemia indication. The company is developing Hemopure for other
indications and is supporting the U.S. Navy's government-funded efforts to
develop a potential out-of-hospital trauma indication. Biopure's veterinary
product Oxyglobin(R) [hemoglobin glutamer - 200 bovine)], or HBOC-301, the
only oxygen therapeutic approved for marketing by both the U.S. Food and
Drug Administration and the European Commission, is indicated for the
treatment of anemia in dogs. Biopure has sold approximately 190,000 units
Contact: Tiana Gorham
Herb Lanzet (Investors)
H.L. Lanzet Inc.
|SOURCE Biopure Corporation|
Copyright©2008 PR Newswire.
All rights reserved